DREB1H Antibody

What is HLA-DRB1 and why is it significant in immunological research?

HLA-DRB1 is a gene that encodes the beta chain of the HLA-DR molecule, which is a major histocompatibility complex (MHC) class II cell surface receptor. This molecule plays a crucial role in antigen presentation to CD4+ T cells, thereby influencing immune responses. HLA-DRB1 is significant in immunological research because specific alleles have been consistently associated with susceptibility to or protection from various autoimmune diseases . The gene contains hypervariable regions that contribute to the peptide-binding specificity of the HLA-DR molecule, affecting antigen presentation capabilities and immune response modulation. Understanding these associations can provide insights into disease mechanisms and potential therapeutic targets.

How do researchers detect and measure HLA-DRB1 antibodies in experimental settings?

Detection and measurement of HLA-DRB1 antibodies typically employ multiple complementary techniques. Flow cytometry represents a primary method, where fluorescently labeled secondary antibodies can be used to detect primary antibodies bound to HLA-DRB1 proteins on cell surfaces . For genetic analysis of HLA-DRB1, restriction fragment length polymorphism (RFLP) analysis using Taq I is commonly employed, followed by polymerase chain reaction (PCR) amplification and hybridization with sequence-specific oligonucleotide probes .

Researchers may also use indirect immunofluorescence, where antibodies are detected using species-specific secondary antibodies conjugated to fluorescent dyes. For quantitative measurements, enzyme-linked immunosorbent assays (ELISAs) can be optimized for HLA-DRB1 antibody detection. In studies requiring high sensitivity, recombinant monoclonal antibodies against HLA-DRB1 can be generated and purified using Protein A Sepharose columns, with typical working concentrations for immunofluorescence ranging from 0.6-2.1 μg/ml depending on the specific antibody variant .

What methodological approaches are used to generate recombinant monoclonal antibodies targeting HLA-DRB1?

Generation of recombinant monoclonal antibodies (rMAbs) targeting HLA-DRB1 involves several key methodological steps:

• Sequence Design and Optimization: The protein sequence is used to design DNA geneblocks optimized for expression in human cells using codon optimization tools. An N-terminal signal peptide sequence is typically added to the geneblock to ensure proper protein secretion .

• Cloning and Vector Construction: The resulting DNA fragments are cloned using Gibson assembly methods into expression vectors (such as modified pEGFP-N1 vectors). For each full-length antibody, both heavy chain (HC) and light chain (LC) plasmids are generated for co-expression .

• Cell Culture and Expression: The constructed plasmids are transfected into HEK293 suspension culture cells (e.g., Expi293F cells) for antibody expression .

• Purification Process:

  • The culture supernatant containing secreted antibodies is harvested and filtered

  • Protein A Sepharose columns are used for antibody purification

  • After binding and washing, antibodies are eluted using low pH elution buffer (0.15 M NaCl, 0.1 M glycine, pH 2.95)

  • The eluate is neutralized with Tris-HCl buffer and dialyzed against PBS

  • The purified antibody is typically concentrated to 1-2 mg/ml

This systematic approach enables the production of highly specific monoclonal antibodies with defined characteristics for research applications.

How can species specificity of HLA-DRB1 antibodies be altered to expand experimental flexibility?

Species specificity of HLA-DRB1 antibodies can be methodically altered through genetic engineering approaches to expand experimental flexibility. This process involves:

• Domain Swapping: Removing the constant regions from both the heavy chain (HC) and light chain (LC) of an existing antibody (e.g., mouse-specific) and replacing them with constant regions from a different species (e.g., rabbit or human IgG) . This maintains the antigen-binding specificity while changing the species recognition.

• Gene Fragment Preparation: Generating PCR fragments corresponding to:

  • Variable regions of the original antibody (HC and LC)

  • Constant regions from the target species (HC and LC)

• Assembly and Expression: Combining these fragments using Gibson assembly into an expression vector for co-transfection into Expi293F cells .

• Validation: Testing the new species-specific antibody variant in immunofluorescence assays to confirm both target recognition and selective binding by the appropriate species-specific secondary antibodies .

This approach allows researchers to generate antibodies with identical antigen recognition but different species specificities (e.g., mouse, rabbit, human). As demonstrated in research, antibodies like rMAb-Hec1 have been successfully converted from mouse (rMAb-Hec1 ms) to rabbit (rMAb-Hec1 rb) and human (rMAb-Hec1 hu) variants, with all variants retaining their ability to recognize the original target while being detected by species-appropriate secondary antibodies .

What approaches can resolve inconsistent detection of HLA-DRB1-associated antibodies across different experimental systems?

Resolving inconsistent detection of HLA-DRB1-associated antibodies requires a systematic troubleshooting approach addressing multiple experimental variables:

• Antibody Format Diversification: Generate multiple antibody formats from the same binding domains, including:

  • Full-length antibodies (IgG)

  • scFvC (single chain variable fragment plus truncated constant region)

  • scFv (single chain variable fragment)

  • Fab (antigen binding fragment)

  Each format offers different advantages for detection sensitivity and specificity across experimental systems.

• Expression System Optimization: When antibodies are undetectable in one system (as observed with RhD-specific antibodies in HLA-DRB1 1501* mice), alternative expression systems should be evaluated . This could involve using different cell lines or host organisms for antibody production.

• Detection Method Multiplexing: Employ complementary detection methods when flow cytometry yields negative results . These include:

  • Western blotting with optimized denaturation conditions

  • Immunoprecipitation to concentrate target antigens

  • ELISA with varied coating antigens and detection strategies

  • Immunohistochemistry with different fixation protocols

• Epitope Accessibility Evaluation: Assess whether conformational changes or masking prevents antibody binding. This can be addressed through:

  • Using different fixation methods (paraformaldehyde, methanol, acetone)

  • Testing detergent permeabilization conditions (Triton X-100 at varying concentrations)

  • Antigen retrieval techniques (heat-induced, enzymatic)

• Cross-Reactivity Analysis: Systematically evaluate cross-reactivity with related epitopes through competitive binding assays and pre-absorption controls.

When troubleshooting detection issues, researchers should systematically document conditions and results in a comprehensive experimental matrix to identify patterns that may reveal the underlying cause of inconsistent detection.

What mechanisms beyond antigen presentation might explain HLA-DRB1 allele associations with autoimmune diseases?

Recent research has uncovered non-antigen presentation (non-AP) mechanisms that explain HLA-DRB1 allele associations with autoimmune diseases. These findings challenge the traditional view that disease associations are exclusively mediated through differential antigen presentation:

• Direct Immune Cell Polarization: Certain HLA-DRB1 alleles directly influence macrophage polarization independent of their antigen presentation function. Risk-associated alleles promote pro-inflammatory "M1" macrophage development, while protective alleles favor anti-inflammatory "M2" macrophage development .

• Short Peptide Immunomodulation: Short synthetic peptides corresponding to the third allelic hypervariable regions of HLA-DRB1 alleles can modulate immune responses even when they are too short for antigen presentation. These AP-incompetent peptides activate distinct transcriptional programs in macrophages .

• Differential Transcriptome Activation: RNA-sequencing analyses reveal that these short HLA-DRB1-derived peptides initiate reciprocal activation of pro-inflammatory versus anti-inflammatory transcriptomes, engaging different gene ontologies and upstream regulators .

This non-AP mechanism represents a paradigm shift in understanding HLA-disease associations, suggesting that HLA molecules have immunomodulatory functions beyond their classical role in antigen presentation. These findings open new avenues for therapeutic interventions that target these alternative pathways in autoimmune disease treatment.

How should researchers optimize antibody concentrations for immunofluorescence experiments with HLA-DRB1?

Optimizing antibody concentrations for immunofluorescence experiments requires a methodical approach based on antibody type, format, and experimental conditions. Based on research data with recombinant antibodies, the following concentration ranges serve as starting points:

Optimization protocol should include:

• Titration series: Test a range of concentrations (0.1-5 μg/ml) under identical conditions.

• Fixation method standardization: Use freshly prepared 4% paraformaldehyde in PHEM buffer (37°C) with 20-minute fixation at room temperature .

• Permeabilization control: Apply 0.1% Triton X-100 in PHEM buffer for consistent epitope accessibility .

• Blocking standardization: Block with 10% boiled donkey serum for 1 hour at room temperature to reduce background .

• Signal-to-noise evaluation: For each concentration, quantify specific signal intensity versus background using digital image analysis.

The optimal concentration provides maximum specific signal with minimal background. This concentration should be validated across different cell types and experimental conditions to ensure reproducibility.

What are the key considerations when designing PCR-based HLA-DRB1 genotyping experiments?

PCR-based HLA-DRB1 genotyping requires careful consideration of several critical factors to ensure accurate results:

• Primer Design Strategy:

  • Design primers targeting conserved regions flanking polymorphic segments

  • Include appropriate restriction sites for subsequent cloning if needed

  • Verify primer specificity using in silico tools to prevent cross-reactivity with related DRB genes (DRB3, DRB4, DRB5)

• Amplification Protocol Optimization:

  • Utilize sequence-specific oligonucleotide probe hybridization for allele determination

  • Combine with restriction fragment length polymorphism (RFLP) analysis using Taq I for comprehensive coverage

  • Implement touchdown PCR protocols to enhance specificity for highly polymorphic regions

• Multiple Gene Analysis Integration:

  • Simultaneously analyze DRB1, DRB5, DQA1, and DQB1 genes for comprehensive haplotype determination

  • Account for potential recombination between haplotypes, as observed between DQB10502-DQA10102 and DQB10301-DQA10501

• Statistical Analysis Planning:

  • Calculate odds ratios (OR) with confidence intervals to quantify allele associations

  • Apply appropriate statistical tests with corrections for multiple comparisons

  • Consider population stratification effects in study design

In a study of 425 Swedish children with insulin-dependent diabetes mellitus (IDDM), this approach successfully identified significant associations between specific HLA-DRB1 alleles and disease risk. The DRB11501-DRB50101-DQB10602-DQA10102 haplotype showed strong negative association with IDDM (OR 0.01; p<0.001), while the DRB11601-DRB50201 haplotype showed positive association (OR 92.0; p<0.001) .

What protocols can researchers use to generate and test antibody fragments for enhanced experimental applications?

Researchers can implement systematic protocols to generate and test antibody fragments with enhanced experimental utility:

• scFvC (Single Chain Variable Fragment plus Truncated Constant Region) Generation:

  • Amplify variable regions of heavy chain (HC) and light chain (LC)

  • Design a flexible linker sequence to connect HC and LC variable regions

  • Attach selected constant regions (typically CH2 and CH3) from rabbit IgG

  • Clone assembled fragments into expression vectors using Gibson assembly

  • Express in Expi293F cells and purify using Protein A Sepharose

• scFv (Single Chain Variable Fragment) Production:

  • Amplify variable regions without constant domains

  • Connect HC and LC variable regions with an optimized flexible linker

  • Clone into expression vectors, optionally fused with reporter proteins like GFP

  • Express in mammalian cells or bacterial systems like E. coli

• Fab (Antigen Binding Fragment) Development:

  • Express truncated HC (variable domain plus CH1) and complete LC

  • Alternatively, enzymatically digest full antibodies with papain

  • Purify using protein L columns that bind kappa light chains

• Fragment Validation Protocol:

  • Confirm binding specificity through immunofluorescence against known targets

  • Test using standardized conditions (PHEM buffer with 0.5% Triton X-100 lysis, 4% paraformaldehyde fixation)

  • Validate species specificity using appropriate secondary antibodies

  • Determine optimal working concentrations through titration (typically 0.5-1.0 μg/ml for scFvC fragments)

These antibody fragments offer several advantages over full-length antibodies, including:

• Improved tissue penetration due to smaller size

• Reduced non-specific binding through Fc receptor interactions

• Better performance in certain applications like live-cell imaging

• Compatibility with phage display for high-throughput screening

• Potential for direct fusion with fluorescent proteins or enzymes

How should researchers analyze contradictory findings between antibody detection methods in HLA-DRB1 studies?

When faced with contradictory findings between antibody detection methods in HLA-DRB1 studies, researchers should implement a structured analysis framework:

• Method-Specific Sensitivity Assessment:

  • Compare detection limits across methods (flow cytometry, ELISA, immunofluorescence)

  • Consider that antibodies may be present but below detection thresholds of certain methods

  • Analyze cases like RhD-specific antibodies that were undetectable by flow cytometry despite evidence of immune response in HLA-DRB1 1501* mice

• Epitope Accessibility Evaluation:

  • Determine if epitope conformation differs between detection platforms

  • Assess if sample preparation methods (fixation, permeabilization) affect epitope recognition

  • Consider native versus denatured protein states in different assays

• Cross-Validation Protocol:

  • Implement orthogonal detection methods for the same samples

  • Use positive and negative controls with known antibody status

  • Apply concentration series to determine if contradictions are concentration-dependent

• Data Integration Framework:

  • Weight results based on assay sensitivity and specificity characteristics

  • Consider biological context when interpreting discrepancies

  • Develop composite scores that integrate multiple detection methods

• Statistical Approach to Contradictions:

  • Apply Bayesian analysis to determine probable true status given multiple test results

  • Calculate concordance rates and discordance patterns across methods

  • Identify systematic biases in particular detection platforms

When analyzing contradictory results, researchers should avoid premature exclusion of negative findings, as demonstrated in studies where erythrocyte-reactive antibody responses were present despite undetectable RhD-specific antibodies by flow cytometry . These apparent contradictions often reveal important biological mechanisms rather than technical failures.

What bioinformatic approaches are most effective for analyzing HLA-DRB1 structure-function relationships?

Effective bioinformatic approaches for analyzing HLA-DRB1 structure-function relationships combine multiple computational methods:

• Three-Dimensional Modeling Techniques:

  • Build models of peptide binding and T-cell recognition sites (α1 and β1 domains)

  • Use established crystal structures (e.g., DR1) as templates for homology modeling

  • Apply these models to analyze subtypes of HLA-DRB1 for physicochemical properties

• Sequence-Structure Correlation Analysis:

  • Identify key polymorphic residues in hypervariable regions

  • Map these residues onto 3D models to identify surface-exposed positions

  • Calculate solvent accessibility of polymorphic residues

• Molecular Dynamics Simulations:

  • Simulate peptide-HLA interactions in physiological conditions

  • Analyze binding pocket flexibility and conformational changes

  • Evaluate hydrogen bonding networks and electrostatic interactions

• Physicochemical Property Calculation:

  • Analyze charge distribution, hydrophobicity, and steric properties

  • Correlate these properties with disease associations

  • Generate quantitative structure-activity relationship (QSAR) models

• Immunoinformatic Peptide Binding Prediction:

  • Implement algorithms to predict peptide binding affinities

  • Compare binding preferences across different HLA-DRB1 alleles

  • Identify potential disease-relevant epitopes

While these approaches are powerful, researchers should be aware of their limitations. A study analyzing five subtypes of DR2-DRB1 found no correlations between DR molecule physicochemical properties and diabetes susceptibility, suggesting that simple structure-based predictions may not fully explain disease associations . This highlights the need to integrate structural analysis with functional experimental data.

How can non-antigen presentation functions of HLA-DRB1 be targeted for therapeutic development?

The discovery of non-antigen presentation (non-AP) functions of HLA-DRB1 opens novel therapeutic avenues that can be explored through several strategic approaches:

• Allelic Epitope-Based Peptide Therapeutics:

  • Develop synthetic peptides based on the third allelic hypervariable regions of protective HLA-DRB1 alleles

  • Design peptides that are AP-incompetent (too short for classical antigen presentation)

  • Target these peptides to promote anti-inflammatory "M2" macrophage polarization

• Transcriptome Modulation Strategies:

  • Identify the key regulatory networks activated by protective HLA-DRB1 alleles

  • Target upstream regulators of anti-inflammatory gene ontologies

  • Develop small molecules or biologics that mimic the transcriptomic effects of protective alleles

• Macrophage Reprogramming Approaches:

  • Design therapies that shift the balance from pro-inflammatory "M1" to anti-inflammatory "M2" macrophages

  • Create delivery systems that target these agents to disease-relevant tissues

  • Combine with conventional immunosuppressants for synergistic effects

• Allele-Specific Antibody Development:

  • Generate antibodies that selectively bind to the third hypervariable region of HLA-DRB1

  • Engineer these antibodies to modulate rather than block HLA-DRB1 function

  • Test in autoimmune disease models for therapeutic efficacy

• Structure-Guided Drug Design:

  • Use three-dimensional models of HLA-DRB1 allelic variants to identify binding pockets

  • Design small molecules that selectively bind risk-associated variants

  • Develop compounds that alter conformation to promote protective signaling

These approaches represent a paradigm shift from traditional strategies that focus on blocking antigen presentation or broad immunosuppression. By targeting the newly discovered immunomodulatory functions of HLA-DRB1, researchers may develop more selective therapies with improved efficacy and reduced side effects for autoimmune diseases.